Jump to section
To remove the uncertainty from cancer treatment decisions, so physicians and patients don’t have to make educated guesses about therapy selection.
About 1 in 5 people develop cancer in their lifetime, so finding better ways to treat it is a priority. Valar Labs is attempting to revolutionise cancer treatments with its AI-driven diagnostics.
The company specialises in analysing tumour microenvironments using computational histology AI (CHAI) tests to predict patient responses to therapies. This approach allows physicians to make informed, patient-specific decisions about cancer treatment, reducing uncertainty and improving outcomes.
The company has published numerous peer-reviewed studies that show its potential across multiple cancer types. Looking ahead, Valar Labs aims to expand its diagnostic capabilities, continuing to enhance precision oncology and improve patient outcomes globally. The significant funding it has raised will certainly help it on its way.
Steph
Company Specialist at Welcome to the Jungle
May 2024
$22m
SERIES A
Apr 2022
$4m
SEED
This company has top investors
Anirudh Joshi
(CEO)Previously worked as a Deep Learning Researcher for PathAI and Curai. Prior to this, they worked as an Applied Scientist in Deep Learning for Microsoft.
Viswesh Krishna
(CTO)Also founded Kanna, and is a Research Assistant at Stanford Artificial Intelligence Laboratory (SAIL).
Damir Vrabac
(COO)Worked as a Machine Learning Intern for iZettle, and was a Researcher for Stanford University in Machine Learning.